Versant Venture Management, LLC Long-Term Concentrated

Location: San Francisco, CA

CIK: 0001560009 · Show all filings

Period: Q4 2014 (Next →)

Filing Date: Apr 23, 2015

Total Value: $104.6B (100.0% shares, 0.0% debt)

Holdings (5)

— Clovis Oncology, Inc. 43.6%

Value $45.63B Shares 814,833 Est. Cost $56000.00 Unrealized —

— Five Prime Therapeutics, Inc. 28.2%

Value $29.49B Shares 1,092,152 Est. Cost $27000.00 Unrealized —

— Achaogen, Inc. 16.0%

Value $16.72B Shares 1,281,152 Est. Cost $13050.00 Unrealized —

— CymaBay Therapeutics, Inc. 9.9%

Value $10.31B Shares 1,048,601 Est. Cost $9830.00 Unrealized —

— Kythera Biopharmaceuticals, Inc. 2.3%

Value $2.441B Shares 70,376 Est. Cost $34680.00 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
—	Clovis Oncology, Inc.	814,833	$45.63B	43.6%	$56000.00	—	Common Stock	189464100
—	Five Prime Therapeutics, Inc.	1,092,152	$29.49B	28.2%	$27000.00	—	Common Stock	33830X104
—	Achaogen, Inc.	1,281,152	$16.72B	16.0%	$13050.00	—	Common Stock	004449104
—	CymaBay Therapeutics, Inc.	1,048,601	$10.31B	9.9%	$9830.00	—	Common Stock	23257D103
—	Kythera Biopharmaceuticals, Inc.	70,376	$2.441B	2.3%	$34680.00	—	Common Stock	501570105